Global Antibiotics Industry

  • October 2010
  • -
  • Global Industry Analysts

This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 197 companies including many key and niche players such as Abbott Laboratories, Astellas Pharma, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., and Toyama Chemical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table Of Contents


ANTIBIOTICS MCP-1705
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


1. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation and Reporting Level 2
Quantitative Techniques and Analytics 3
Product Definitions and Scope of Study 3
Penicillin 4
Cephalosporins 4
Macrolides 4
Quinolones 4
Carbapenems 4
Other Antibiotics 5
Aminoglycosides 5
Tetracyclines 5
Sulfonamides 5
Mupirocin 5
Glycopeptides 5
Synercid 6
Oxazolidinones 6
Linezolid 6

2. INDUSTRY OVERVIEW 7
Antibiotic Resistance and Generic Competition to Impact Long
Term Growth 7
New Regulations Guiding Usage of Drugs to Drive Growth 7
Current and Future Analysis 7

3. MARKET DYNAMICS 9
Anti-Bacterials Segment Drives Global Anti- Infectives Market 9
Antibiotic Resistance - A Primary Growth Inhibitor 9
Antibiotic-Resistant Bacteria by Type 9
Patent Expiries Commoditize Antibiotics 10
Patent Expiries of Leading Drugs in the Recent Past, Current,
and Future (2000 -2013) 10
Anti-MRSA Antibiotics Find Their Way 10
Table 1: World MRSA Treatments (2007 and 2008) : Percentage
Share Breakdown by Leading Antibiotic Drugs -Vancomycin,
Zyvox, Cubicin and Tygacil (includes corresponding
Graph/Chart) 11
Key Antibiotics in Pipeline 11

4. COMPETITION 12
Highly Competitive Market 12
Table 2: Leading Players in the Worldwide Antibiotics Market
(2008): Percentage Breakdown by Value Sales for Pfizer, Glaxo
Smithkline, Sanofi-aventis, Johnson and Johnson, Bayer, Abbott,
Wyeth, and Others (includes corresponding Graph/Chart) 12
GlaxoSmithKline - The Undisputed Leader of Penicillin Market 13
Table 3: Worldwide Leading Antibiotics within Penicillin
Class (2005 and 2006): Percentage Breakdown by Value for
Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes
corresponding Graph/Chart) 13
GlaxoSmithKline Leads Cephalosporin Market 14
Table 4: Worldwide Leading Antibiotics within Cephalosporin
Class (2005 and 2006): Percentage Breakdown by Value for
Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil,
Cefzon, Flumarin, and Others (includes corresponding
Graph/Chart) 14
Pfizer Dominates Macrolides Market 15
Table 5: Worldwide Leading Antibiotics within Macrolide Class
(2005 and 2006): Percentage Breakdown by Value for Zithromax,
Klaricid/Biaxin, Ketek, and Others (includes corresponding
Graph/Chart) 15
Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic 16
Table 6: Worldwide Leading Antibiotics within Quinolone Class
(2005 and 2006): Percentage Breakdown by Value for
Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and
Others (includes corresponding Graph/Chart) 16
Merck Rules Carbapenems Market 17
Table 7: Worldwide Leading Antibiotics within Carbapenem
Class (2005 and 2006): Percentage Breakdown by Value for
Primaxin, Merrem, Invanz, and Others (includes corresponding
Graph/Chart) 17

5. PRODUCT OVERVIEW 18
Antibiotics - An Introduction 18
Antibiotic Resistance 18
b-Lactams 19
Classification of Antibiotics 20
Key Milestones in Antibiotic Development 20
Antibiotic Types 20
Penicillin 20
History 21
About the Drug 21
Cephalosporins 21
Treatment 22
Effects of the Drug 22
Macrolides 22
Treatment 23
Quinolones 23
Table 8: Leading Global Ciprofloxacin Brands: (2006-2008)
(includes corresponding Graph/Chart) 23
Carbapenems 24
Other Antibiotics 24
Aminoglycosides 24
Treatment 24
Effects of the Drug 24
Tetracyclines 25
Treatment 25
Effects of the Drug 26
Sulfonamides 26
Treatment 26
Effects of the Drug 27
Mupirocin 27
Glycopeptides 27
Synercid 27
Oxazolidinones 28
Linezolid 28

6. RESEARCH FINDINGS 29
New Design for Monitoring Toxin Delivery Activity of
Pathogenic Bacteria 29
Cephalosporins Effective when Compared to Penicillin 29
FDA Bans Baytril Antibiotic for Chickens 29
Erythromycin Along with Some Specific Drugs Increase Risk of
Sudden Death 29
Rise in Usage of Quinolones for Urinary Tract Infections Leads
to Drug Resistance 30
Polyphor Discovers POL7080 - New Antibiotic Against Gram-
Negative Bacteria 30

7. FDA APPROVALS/PATENTS 31
MiddleBrook Obtains NDA Approval for MOXATAGâ„¢ 31
JandJPRD Seeks FDA Approval for Doripenem Antibiotic 31
JandJPRD Seeks FDA Approval for Investigational Antibiotic,
Ceftobiprole 31
GSK Receives Approval for ALTARGO® in Europe 31
APL Receives FDA Approval for Cefpodoxime Proxetil 32
Cubist Receives Approval to Market CUBICIN in Canada 32
Cubist Obtains Approval to Market CUBICIN for Added
Indications in EU 32
Cubist Gains Approval for CUBICIN in Taiwan and South Korea 32
Cethromycin Achieves FDA’s Orphan Drug Designation 32
FDA Approves Wockhardt’s Cefotaxime Injection 33
FDA Approves Doxycycline Tablets 33
FDA Approves Clarithromycin 33
FDA Approves Doxycycline Tablets For The US Market 33
Johnson and Johnson Applies Doripenem For FDA Approval 33
FDA Certifies Antibioticos do Brasil’s Plant 33
FDA Certifies ANDA For Cefdinir Capsules 34
US FDA Approves Teva’s Cefprozil Tablets 34
FDA Certifies ANDA for Cephalexin Capsules 34
American Pharmaceutical Partners Receives FDA Approvals for
Ceftriaxone for Injection, USP 34
Advancis’s Keflex Receives FDA Approval 34
Wockhardt Gains Marketing Approval for Cefuroxime axetil in
the US 34
Wyeth’s Mylotarq Receives Government’s Approval 35
FDA Approves Generic Version of Zithromax 35
Pfizer Wins FDA Approval for Zmaxâ„¢ 35
Venus Remedies Files Second PCT for New Cephalosporins 36
Falcon Gains US FDA Approval for its Generic Anti-Infective
Solution 36
Cadilla Receives FDA Approval to Market Clindamycin 36

8. RECENT INDUSTRY ACTIVITY 37
DSM Opens Eco-friendly Antibiotics Plant ZOR-f, in the
Netherlands 37
Daiichi Leverages Ranbaxy’s Network to Market Tavanic in South
Africa and Romania 37
Pfizer Acquires Wyeth 37
Durata Therapeutics Acquires Pfizer’s Vicuron Pharmaceuticals 37
Cubist Completes Acquisition of Calixa Therapeutics 38
AstraZeneca to Acquire Novexel 38
Tianyin and Sichuan Mingxin to Establish an Antibiotic Joint
Venture 38
Pfizer and Aurobindo Pharma Ink Agreement for Producing Off
Patent Drugs 39
BMP Sunstone to Acquire Majority Stake in Zhangjiakou Shengda 39
Novartis to Take Over Protez Pharmaceuticals 39
3i to Buy Alpharma Unit 40
NCPC to Acquire Stake in DSM’s Antibiotics Division 40
ULL Establishes New Antibiotics Unit in Himachal Pradesh 40
Biocat to Expand Presence in the Indian Market 40
PRWT Acquires Cherokee Chemical Unit from Merck 40
CSPC Joins Hands with Indonesian Firms 41

9. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST - A
PERSPECTIVE BUILDER 42
Nisshin-Kyorin to Merge with Kyorin Pharmaceutical 42
Schering-Plough Acquires Organon BioSciences 42
GSK and Anacor Partner for Boron Chemistry-Based Antibiotics and
Antivirals 42
Iroko Bags Canadian Rights to Vancocin® 43
Cubist Licenses CUBICIN Rights to Merck 43
Sagent Partners with Astral to Develop Injectable Antibiotics 43
MR Healthcare to Manufacture New Antibiotics and Medicines 43
Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo 44
CandO Pharmaceutical to Distribute Meiact in China 44
Bioton Signs Deal to Market Antibiotics in Russia 44
Toyama Gains Marketing Approval for Geninax® in Japan 44
Forest Laboratories Acquires Cerexa 44
Oscient Modifies Licensing Agreement With LG Life Sciences 44
Orchid Sign Licensing and Distribution Pact With Actavis 45
Forest Laboratories Revokes Partnership With Replidyne 45
SRI and Blanca Collaborate To Develop and Test Carbacephem 45
AstraZeneca To Expand Research Center For Antibiotics 45
Jade Pharmaceutical Begins Levofloxacin’s Production in China 45
Reyoung To Start Antibiotic Production At New Facility 46
Toyama Begins T-705 Clinical Trials 46
SmPC For Sanofi-Aventis’ Ketek® Updated 46
Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic
Tablets in France 46
Antibiotice Plans To Infuse Funds For Antibiotics Production 46
UAE Approves Pfizer’s Zithromax SD 46

10. PRODUCT INNOVATIONS/INTRODUCTIONS 47
Janssen-Cilag Launches Doribaxâ„¢ - New Carbapenem Antibiotic 47
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin 47
Watson Pharma Introduces Biaxin XL’s Generic Version 47

11. PRODUCT INNOVATIONS IN THE RECENT PAST - A PERSPECTIVE BUILDER 48
Toyama Launches New Garenoxacin Quinolone Antibiotic 48
Wockhardt to Introduce Cefprozil in the US 48
MSD India Launches Invanza in India 48
Orchid Chemicals to Introduce Three New Drugs in the US 48
DUSA Pharmaceuticals Releases ClindaReachâ„¢ 49
Mylan Releases Cipro’s Generic Version 49
Macrolide Antibiotic Developed In the US 49
University of Michigan Devises NMR Spectroscopy For Antibiotics 49
Glycopeptide-Cephalosporin Antibiotics Developed In The US 49
Neosil Tests NEO 101 Antibiotic 49
New Antibiotic Developed By Canadian Inventors 49
Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada 50
Penicillin Binding Protein Found In Japan 50
Venus Remedies Releases Mucomelt-Forte 50

12. FOCUS ON SELECT GLOBAL PLAYERS 51
Abbott Laboratories (USA) 51
Astellas Pharma, Inc. (Japan) 51
Bayer HealthCare AG (Germany) 51
Bristol-Myers Squibb Co. (USA) 52
Cubist Pharmaceuticals, Inc. (USA) 52
Daiichi Sankyo Company, Limited (Japan) 53
Eli Lilly and Co. (USA) 54
GlaxoSmithKline Plc (UK) 54
Johnson and Johnson (USA) 55
Kyorin Pharmaceutical Co., Ltd. (Japan) 55
LG Life Sciences Limited (Korea) 56
MiddleBrookâ„¢ Pharmaceuticals, Inc. (USA) 57
Novartis AG (Switzerland) 57
Pfizer Inc. (USA) 58
Pliva d.d. (Croatia) 59
Roche (Switzerland) 59
Sanofi-Aventis SA (France) 59
Takeda Pharmaceutical Company, Ltd. (Japan) 60
Toyama Chemical Co., Ltd. (Japan) 60

13. GLOBAL MARKET PERSPECTIVE 61
Table 9: World Recent Past, Current and Future Analysis for
Antibiotics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 61

Table 10: World Historic Review for Antibiotics by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 62

Table 11: World 11-Year Perspective for Antibiotics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 63

Table 12: World Recent Past, Current and Future Analysis for
Penicillin by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 64

Table 13: World Historic Review for Penicillin by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 65

Table 14: World 11-Year Perspective for Penicillin by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 66

Table 15: World Recent Past, Current and Future Analysis for
Cephalosporin by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 67

Table 16: World Historic Review for Cephalosporin by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 68

Table 17: World 11-Year Perspective for Cephalosporin by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 69

Table 18: World Recent Past, Current and Future Analysis for
Macrolides by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 70

Table 19: World Historic Review for Macrolides by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 71

Table 20: World 11-Year Perspective for Macrolides by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 72

Table 21: World Recent Past, Current and Future Analysis for
Quinolones by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 73

Table 22: World Historic Review for Quinolones by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 74

Table 23: World 11-Year Perspective for Quinolones by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 75

Table 24: World Recent Past, Current and Future Analysis for
Carbapenems by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 76

Table 25: World Historic Review for Carbapenems by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 77

Table 26: World 11-Year Perspective for Carbapenems by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 78

Table 27: World Recent Past, Current and Future Analysis for
Other Antibiotics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 79

Table 28: World Historic Review for Other Antibiotics by
Geographic Region - US, Canada, Jap an, Europe, Asia- Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 80

Table 29: World 11-Year Perspective for Other Antibiotics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 81

14. THE UNITED STATES 82
A.Market Analysis 82
Current and Future Analysis 82
Antibiotics Approved Between 2000 and 2005 in the United
States 82
Competition 83
Table 30: Leading Players in the US Antibiotics Market
(2008): Percentage Breakdown by Value Sales for Pfizer,
Johnson and Johnson, GlaxoSmithKline, Abbott, and Others
(includes corresponding Graph/Chart) 83
Key Players 83
B.Market Analytics 84
Table 31: US Recent Past, Current and Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 84

Table 32: US Historic Review for Antibiotics by Product
Segment - Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics MarketsIndependently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 85

Table 33: US 11-Year Perspective for Antibiotics by Product
Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 86

15. CANADA 87
A.Market Analysis 87
Current And Future Analysis 87
B.Market Analytics 87
Table 34: Canadian Recent Past, Current and Future Analysis
for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 87

Table 35: Canadian Historic Review for Antibiotics by
Product Segment - Penicillin,Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 88

Table 36: Canadian 11-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 89

16. JAPAN 90
A.Market Analysis 90
Current and Future Analysis 90
Key Players 90
B.Market Analytics 91
Table 37: Japanese Recent Past, Current and Future Analysis
for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 91

Table 38: Japanese Historic Review for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 92

Table 39: Japanese 11-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 93

17. EUROPE 94
A.Market Analysis 94
Current and Future Analysis 94
B.Market Analytics 95
Table 40: European Recent Past, Current and Future Analysis
for Antibiotics by Geographic Region - France, Germany,
Italy, UK, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 95

Table 41: European Historic Review for Antibiotics by
Geographic Region - France, Germany, Italy, UK, Spain, and
Rest of Europe Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 96

Table 42: European Recent Past, Current and Future Analysis
for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 97

Table 43: European Historic Review for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems, and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 98

Table 44: European 11-Year Perspective for Antibiotics by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 99

Table 45: European 11-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems, and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 100

17a. FRANCE 101
A.Market Analysis 101
Current and Future Analysis 101
Trends 101
Over Consumption of Antibiotics - Cause of Concern 101
Sanofi-Aventis SA - A Key Player 101
B.Market Analytics 102
Table 46: French Recent Past, Current and Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 102

Table 47: French Historic Review for Antibiotics by Product
Segment - Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 103

Table 48: French 11-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for2005, 2010 and
2015 (includes corresponding Graph/Chart) 104

17b. GERMANY 105
A.Market Analysis 105
Current and Future Analysis 105
Bayer HealthCare AG - A Key Player 105
B.Market Analytics 106
Table 49: German Recent Past, Current and Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 106

Table 50: German Historic Review for Antibiotics by Product
Segment - Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 107

Table 51: German 11-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 108

17c. ITALY 109
A.Market Analysis 109
Current and Future Analysis 109
B.Market Analytics 109
Table 52: Italian Recent Past, Current and Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides, Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 109

Table 53: Italian Historic Review for Antibiotics by Product
Segment - Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 110

Table 54: Italian 11-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 111

17d. THE UNITED KINGDOM 112
A.Market Analysis 112
Current And Future Analysis 112
GlaxoSmithKline Plc - A Key Player 112
B.Market Analytics 113
Table 55: UK Recent Past, Current and Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 113

Table 56: UK Historic Review for Antibiotics by Product
Segment - Penicillin, Cephalosporin, acrolides, Quinolones,
Carbapenems and Other Antibiotics Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 114

Table 57: UK 11-Year Perspective for Antibiotics by Product
Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for2005, 2010 and
2015 (includes corresponding Graph/Chart) 115

17e. SPAIN 116
Market Analysis 116
Table 58: Spanish Recent Past, Current and Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 116

Table 59: Spanish Historic Review for Antibiotics by Product
Segment - Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 117

Table 60: Spanish 11-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 118

17f. REST OF EUROPE 119
A.Market Analysis 119
Current and Future Analysis 119
Poland 119
Table 61: Polish Market for Antibiotics (2008): Percentage
Breakdown of Market Share by Leading Companies - GSK
Pharma, Bioton, Sandoz Corp, Ranbaxy and Others (includes
corresponding Graph/Chart) 119
Focus On Select Players 119
B.Market Analytics 120
Table 62: Rest of Europe Recent Past, Current and Future
Analysis for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 120

Table 63: Rest of Europe Historic Review for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 121

Table 64: Rest of Europe 11-Year Perspective for Antibiotics
by Product Segment - Percentage Breakdown of Dollar Sales
for Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 122

18. ASIA-PACIFIC 123
A.Market Analysis 123
Current and Future Analysis 123
India 123
Rising Prices of Penicillin G to Affect Antibiotics Production 123
Market for Injectable Antibiotics Poised to Grow 123
Cipla, Pharmaceutical Market Leader in 2009 124
China 124
Carbapenem Witnesses Robust Growth in China 124
Key Players 125
Ranbaxy Laboratories Ltd. (India) 125
B.Market Analytics 126
Table 65: Asia-Pacific Recent Past, Current and Future
Analysis for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 126

Table 66: Asia-Pacific Historic Review for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 127

Table 67: Asia-Pacific 11-Year Perspective for Antibiotics
by Product Segment - Percentage Breakdown of Dollar Sales
for Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 128

19. REST OF WORLD 129
A.Market Analysis 129
Current and Future Analysis 129
B.Market Analytics 130
Table 68: Rest of World Recent Past, Current and Future
Analysis for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 130

Table 69: Rest of World Historic Review for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 131

Table 70: Rest of World 11-Year Perspective for Antibiotics
by Product Segment - Percentage Breakdown of Dollar Sales
for Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2005, 2010 and
2015 (includes corresponding Graph/Chart) 132


COMPETITION

Total Companies Profiled: 197 (including Divisions/Subsidiaries - 238)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 48
Canada 8
Japan 11
Europe 68
France 7
Germany 10
The United Kingdom 8
Italy 10
Spain 4
Rest of Europe 29
Asia-Pacific (Excluding Japan) 87
Middle East 11
Latin America 4
Africa 1
------------------------------------------

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.